Congruence, a computationally-driven biotechnology company, has successfully closed a US $32 million financing round to advance its pipeline of pharmacological correctors for diseases caused by protein misfolding. This funding will primarily support the company’s lead program, CGX-926, which is the first clinical candidate addressing MC4R-deficient (MC4R-d) genetic obesity. This is a serious and debilitating condition for which there are currently no effective treatments. Congruence plans to file a Clinical Trial Application (CTA) in the second half of 2025 and initiate a Phase 1 trial in early 2026. This trial will include a Phase 1b efficacy cohort specifically for MC4R-d patients, aiming to generate the first clinical proof-of-concept data for this condition.

In addition to its lead program, the new funding will also enable Congruence to advance its other key programs into late preclinical testing, including those targeting GBA1-driven Parkinson's disease and Alpha-1 antitrypsin (A1AT) deficiency. The company utilizes its proprietary computational drug discovery platform, Revenir™, which analyzes the dynamic biophysical changes in mutated proteins to predict how small molecules can correct the underlying pathogenic defects. This approach has allowed the company to build a pipeline of wholly-owned drugs and to establish multi-target research collaborations with large pharmaceutical companies, including Ono Pharmaceuticals and another undisclosed partner. The new financing round, which saw participation from all existing investors, highlights the confidence in Congruence's unique, computationally-driven approach to addressing a variety of high-value, genetically validated, and difficult-to-drug targets. The company’s mission is to provide new hope and effective treatments for patients with these devastating genetic conditions.